Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated

被引：0
|
作者：
Fang, W. F. [1 ]
Bu, Q. [2 ]
Wang, Q. M. [3 ]
Zhao, W. H. [4 ]
Wang, L. P. [5 ]
Dong, X. R. [6 ]
Chen, P. F. [7 ]
Wen, Z. B. [8 ]
Jia, J. [9 ]
Jiang, G. M. [9 ]
Zhang, L. [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China
[5] Baotou Canc Hosp, Baotou, Peoples R China
[6] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[7] Zhuji Peoples Hosp, Zhuji, Peoples R China
[8] Peoples Hosp Gaozhou, Gaozhou, Peoples R China
[9] Dongguan Peoples Hosp, Dongguan, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
aumolertinib; high-dose; uncommon EGFR mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-07
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [21] Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients
    Wang, Chunsheng
    Zhao, Kewei
    Hu, Shanliang
    Dong, Wei
    Gong, Yan
    Li, Minghuan
    Xie, Conghua
    LUNG CANCER, 2022, 172 : 86 - 93
  • [22] Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report
    Christopoulos, Petros
    Herster, Franziska
    Hoffknecht, Petra
    Falk, Markus
    Tiemann, Markus
    Kopp, Hans-Georg
    Althoff, Andre
    Stammberger, Anja
    Laack, Eckart
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [23] Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results
    Fang, S.
    Xu, T.
    Liu, N.
    Wang, X. Y.
    Cheng, W. W.
    Fang, H. H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S650 - S650
  • [24] A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)
    Miura, S.
    Hsia, T.
    Hung, J.
    Jung, H. A.
    Shih, J.
    Park, C.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1115 - S1116
  • [25] Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study
    Yao, B.
    Yang, L. F.
    Ran, T.
    Deng, S.
    Xu, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S666 - S667
  • [26] Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases
    Yang, J. Y. C-H.
    Schuler, M.
    Popat, S.
    Miura, S.
    Park, K.
    Passaro, A.
    de Marinis, F.
    Solca, F.
    Marten, A.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S965 - S965
  • [27] Efficacy and Safety of Chemotherapy or EGFR-TKIs as First-Line Therapy in NSCLC Patients Harboring Non-Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
    Liao, Chen
    Bai, Li
    He, Tingting
    Liang, Qingle
    Hu, Defeng
    Lei, Shipeng
    He, Yong
    Wang, Yubo
    CANCER MEDICINE, 2025, 14 (01):
  • [28] Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia
    Tan, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S396 - S397
  • [29] Efficacy and Safety of Aumolertinib with Radiotherapy in the Treatment of Unresectable Locally Advanced EGFR-Mutant NSCLC: A Phase II Study
    Meng, X.
    Kong, L.
    Zhao, K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S581 - S581
  • [30] Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina
    Kaen, D.
    Tsou, F.
    Lupinacci, L.
    Puparelli, C.
    Minatta, J.
    Rizzo, M.
    Berutti, S.
    Di Giovanni, R.
    Ferreira, Y.
    Recondo, G.
    Carranza, O.
    Flores, M.
    Aman, E.
    Di Mario, G.
    Pini, A.
    Castagneris, N.
    Roa, M.
    Enrico, D.
    Martin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S667 - S668
12345